Difference between revisions of "Fludarabine (Fludara)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4067b1_15_fludarabine%20label.pdf Fludarabine (Fludara) package ...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4067b1_15_fludarabine%20label.pdf Fludarabine (Fludara) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/fludarabine.pdf Fludarabine (Fludara) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.<ref name="insert">[http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4067b1_15_fludarabine%20label.pdf Fludarabine (Fludara) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/fludarabine.pdf Fludarabine (Fludara) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
Revision as of 01:21, 16 January 2012
General information
Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Fludarabine (Fludara) patient drug information (Chemocare)[3]
- Fludarabine (Fludara) patient drug information (UpToDate)[4]